Metabolomics in renal cell carcinoma: From biomarker identification to pathomechanism insights.

Renal cell carcinoma (RCC) is a frequently diagnosed cancer with high prevalence, which is inversely associated with survival benefit. Although myriad studies have shed light on disease causality, unfortunately, thus far, RCC diagnosis is faced with numerous obstacles partly due to the insufficient knowledge of effective biomarkers, hinting deeper mechanistic understanding are urgently needed. Metabolites are recognized as final proxies for gene-environment interactions and physiological homeostasis as they reflect dynamic processes that are ongoing or have been taken place, and metabolomics may therefore offer a far more productive and cost-effective route to disease discovery, particularly within the arena for new biomarker identification. In this review, we primarily expatiate recent advances in metabolomics that may be amenable to novel biomarkers or therapeutic targets for RCC, which may expand our armaments to win more bettles against RCC. Copyright © 2020 Elsevier Inc. All rights reserved.

Citation

Yuan-Yuan Chen, He-He Hu, Yan-Ni Wang, Jing-Ru Liu, Hai-Jing Liu, Jian-Ling Liu, Ying-Yong Zhao. Metabolomics in renal cell carcinoma: From biomarker identification to pathomechanism insights. Archives of biochemistry and biophysics. 2020 Nov 30;695:108623

Mesh Tags

Substances

PMID: 33039388

search → result